Novo Nordisk A/S (BKK:NOVOB80)

Market Cap	5.51T -51.6%
Revenue (ttm)	1.53T +6.4%
Net Income	507.86B +1.4%
EPS	114.18 +1.8%
Shares Out	n/a
PE Ratio	10.85
Forward PE	11.83
Dividend	0.04 (3.36%)
Ex-Dividend Date	Mar 27, 2026

Volume	1,676,488
Average Volume	3,207,290
Open	1.210
Previous Close	1.200
Day's Range	1.190 - 1.240
52-Week Range	1.120 - 2.700
Beta	n/a
RSI	44.82
Earnings Date	May 6, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 69,505
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: NOVOB80

Financial Performance

In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.

Financial numbers in DKK